MDACC Study No:2013-0907 ( NCT No: NCT02029443)
Title:A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects with Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Principal Investigator:William G. Wierda
Treatment Agent:ACP-196
Study Status:Open
Study Description:The goal of Part 1 of this clinical research study was to find the highest
tolerable dose of ACP-196 that could be given to patients with CLL. Part 1 is
now over.

The goal of Part 2 of this study is to learn if ACP-196 can help to control
CLL. The safety of this drug is being studied in both parts.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:ACP-196
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Acerta Pharma BV
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:William G. Wierda
For Clinical Trial Enrollment:713-745-0428
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults